Fast Locator 2011-2012: Lonza - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Lonza



A HISTORY OF INNOVATION
In 1897, Lonza was founded on the banks of the river Lonza in the Swiss Alps by adventurous entrepreneurs. Today, Lonza continues to embody that pioneering spirit as a leading innovator and partner for the pharmaceutical, healthcare, nutrition, personal care, cosmetic, industrial biotech and life science industries.

PROVEN TRACK RECORD
For over 25 years, Lonza Custom Manufacturing has been helping emerging and large biotechnology and pharmaceutical companies improve and advance their products. Whether for clinical or commercial supply, Lonza’s complete set of development services, industry-leading manufacturing processes, and broad chemical and biotechnology platforms enable your products to reach their full potential.

EXTENSIVE CAPABILITIES & EXPERIENCE
Active pharmaceutical ingredients (APIs), highly potent APIs, advanced intermediates, fine chemicals, nutraceuticals, cosmeceuticals, antibody drug conjugates, peptides, vaccines, plasmid DNA, recombinant novel proteins, monoclonal antibodies, antibody fragments, cell-based therapeutics, research products and media services … Lonza has the know-how and experience to handle almost any pharmaceutical or biotechnology challenge, around the globe.


COMPLETE PROCESS R&D SERVICES:

  • AggreSolve Protein Aggregation Predictor
  • The GS Gene Expression System
  • XS Microbial Expression Technologies
  • Cell line construction
  • Strain design
  • Bio/catalyst design
  • Process development
  • Process scale-up
  • Process validation
  • Process transfer
  • Technology development
  • Regulatory support

WORLDWIDE, STATE-OF-THE-ART FACILITIES
North America: Portsmouth, NH; Hopkinton, MA; Walkersville, MD
Europe: Slough, UK; Kourim, CZ; Porrino, ES; Braine, BE; Verviers, BE
Asia: Nansha, CN; Singapore, SG


Contact:

Lonza
Muenchensteinerstr. 38
CH-4002 Basel
Switzerland
+41 61 316 8111
contact@lonza.com

Website:

www.lonza.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here